SLU-PP-332

SLU-PP-332 is not a peptide. It is a small synthetic molecule that activates the estrogen-related receptors ERR alpha, beta and gamma, studied as an exercise mimetic. Every published result is from mice or cultured cells. No human trial has been published, and no regulator in Vietnam or anywhere else has approved it.

Last updated: September 2026

What is SLU-PP-332?

SLU-PP-332 is a synthetic agonist of the estrogen-related receptors, a family of three orphan nuclear receptors written ERR alpha, ERR beta and ERR gamma. It was reported in 2023 by Billon and colleagues at the Center for Clinical Pharmacology, Washington University School of Medicine and St. Louis College of Pharmacy, as a chemical tool for activating all three receptors in living animals. Most compounds in our peptide library are chains of amino acids. This one is not, and calling it a peptide is a labelling habit from the research chemical market rather than a description of the molecule.

The interest is in what the receptors do. ERRs govern genes for mitochondrial biogenesis, oxidative phosphorylation and fatty acid oxidation, which is the same machinery that adapts when a person trains. Activating them pharmacologically is described in the literature as an exercise mimetic strategy. A 2026 systematic review of the preclinical work put the position plainly: clinical trials are still needed to confirm efficacy and safety in humans.

Compare that evidence base to what sits beside it here. MOTS-c and NAD+ occupy the same mitochondrial territory with their own limits. SLU-PP-332 is at an earlier stage than either: there is no human dose, no human side effect profile, and no human timepoint, because there is no human study.

How It Works

Pan-ERR activation: the original report identifies SLU-PP-332 as a synthetic agonist that targets all three ERR subtypes, with the highest potency for ERR alpha (PMID 36988910).

Acute exercise gene programme: in mice the compound induces DNA damage-inducible transcript 4 (Ddit4), a gene induced by acute aerobic exercise, at levels matching or exceeding treadmill running depending on the muscle examined (PMID 41421047).

Mitochondrial output: SLU-PP-332 increases mitochondrial function and cellular respiration in a skeletal muscle cell line, and the mouse work reports a shift toward type IIa oxidative fibres (PMID 36988910).

Fatty acid metabolism: in mouse obesity models the compound raised energy expenditure and fatty acid oxidation, and in a cardiac model the authors show ERR gamma is the main mediator of the transcriptional response (PMID 37739806, PMID 37961903).

Benefits

Increased type IIa oxidative skeletal muscle fibres and enhanced exercise endurance (animal study, mice, PMID 36988910)
Increased energy expenditure and fatty acid oxidation with decreased fat mass accumulation (animal study, diet-induced obese and ob/ob mice, PMID 37739806)
Reduced obesity and improved insulin sensitivity in models of metabolic syndrome (animal study, mice, PMID 37739806)
Improved ejection fraction, less fibrosis and increased survival in a pressure overload heart failure model (animal study, mice, PMID 37961903)
Reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in the aging kidney (animal study, 21-month-old mice, PMID 37717940)
Increased mitochondrial function and cellular respiration in a skeletal muscle cell line (cell study, no animals, PMID 36988910)
Reduced cytotoxicity, oxidative stress and senescence, and abundant myotube formation, in myoblasts cultured from inactive women (cell study, human cells in a dish, not a human trial, PMID 40692696)

Dosing Described in Research and Labels

Phase	Dose	Frequency	Duration
Mouse: exercise endurance	dose not stated in the abstract (animal study, mouse, route not stated in the abstract, PMID 36988910)	The abstract states only that the compound was administered to mice	Not stated in the abstract
Mouse: exercise capacity, route stated	dose not stated in the abstract (animal study, mouse, intraperitoneal, PMID 41421047)	Intraperitoneal injection. The authors note SLU-PP-332 lacks oral bioavailability, which is why they built an orally active analogue	Not stated in the abstract
Mouse: obesity and metabolic syndrome	dose not stated in the abstract (animal study, diet-induced obese and ob/ob mice, route not stated in the abstract, PMID 37739806)	Not stated in the abstract	Not stated in the abstract
Mouse: aging kidney	dose not stated in the abstract (animal study, 21-month-old mice, route not stated in the abstract, PMID 37717940)	Not stated in the abstract	8 weeks of treatment (PMID 37717940)
Human use	No established human dose	Not established	Not established

These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.

Side Effects

Common

⚠No human side effect profile exists, because no human trial of SLU-PP-332 has been published
⚠A 2026 systematic review of the preclinical literature reports that SLU-PP-332 reduced adiposity, improved glycemic control and raised basal energy expenditure in obesity models without evident toxicity (PMID 42024694)
⚠Nothing in the abstracts describes an injection site reaction, a laboratory abnormality or a tolerability finding of any kind in a person

Rare

•Not characterised. With no published human study there is no rare event data, no frequency table and no long-term follow-up for this compound
•Anything quoted online as a side effect rate is a report from users rather than a trial (community practice, no trial)

Who Should NOT Use SLU-PP-332

✕Anyone tested under anti-doping rules. The World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators in sport, and two 2026 papers published SLU-PP-332 metabolite profiles specifically to support detection (PMID 41688415, PMID 41588687)
✕Anyone expecting a known human safety profile. There is not one, and the preclinical reviews themselves say clinical trials are needed before efficacy and safety in humans can be claimed (PMID 42024694)
✕Pregnancy or breastfeeding. No safety data of any kind exists in people

What to Expect

Any human timepoint

No published human study exists, so no source measures anything at week 1, week 4 or any other point in a person. The trials did not report weekly timepoints because the trials do not exist. Anything you see described as a week by week progression is (community practice, no trial).

Mouse study: 8 weeks

The aging kidney work treated 21-month-old mice for 8 weeks and reported tissue and biomarker outcomes such as albuminuria and podocyte loss (PMID 37717940). That is a mouse timeline measured in a laboratory, not something a person would notice.

Mouse study: endurance

The original report describes increased type IIa oxidative muscle fibres and enhanced exercise endurance in mice, with no timepoint stated in the abstract (PMID 36988910).

What is not known

No abstract reports a human dose, a human timepoint, a human side effect rate, or how long any effect lasts. The animal study conditions are study conditions, not a recommendation, and they do not convert to a human schedule.

Notes from Ho Chi Minh City

SLU-PP-332 reaches Ho Chi Minh City the way most research chemicals do, as a line item on a vendor price list rather than as a paper anyone has read. It gets pitched in District 2 and District 7 gym conversations as exercise in a bottle, which is a fair translation of the phrase the researchers themselves use, exercise mimetic. What gets left out is that the phrase describes a gene expression pattern in mouse muscle, not a result in a person. There is no human study to argue about, so every number quoted at you in a gym here traces back to a mouse or a cell culture plate. Two practical local notes. It is not a peptide, so the reconstitution and cold chain habits people have built around BPC-157 and the GLP-1s do not automatically apply. And anyone competing under a federation that follows WADA rules, which includes the local triathlon and powerlifting scenes, should know that detection assays for its metabolites were published in 2026. Any decision about using an unapproved research compound belongs with a licensed physician, not a price list.

Sourcing in Vietnam

SLU-PP-332 is not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam, and it is not an approved medicine in any country. There is no branded product, no marketing authorisation, and no clinic here that prescribes it. This site lists no verified supplier for it, and no price is quoted here because there is no legitimate supply chain to quote from. That also means there is no reference standard to check a certificate of analysis against in the way there is for the common research peptides, so a COA supplied with it proves less than it would for BPC-157 or semaglutide. Treat anything offered as unverified.

FAQ

Q: Is SLU-PP-332 a peptide?

A: No. It is a small synthetic molecule that acts as an agonist at the estrogen-related receptors ERR alpha, beta and gamma. It is sold beside peptides on research chemical price lists, which is why it gets grouped with them, but it is a different class of compound entirely.

Q: Has SLU-PP-332 been tested in humans?

A: No published human trial exists. A 2026 systematic review covering the 2020 to 2024 literature examined only animal and cell models and concluded that clinical trials are needed to confirm efficacy and safety in humans (PMID 42024694). One 2025 study did treat human cells with it, but those were myoblasts cultured from muscle biopsies in a laboratory, not people (PMID 40692696).

Q: What dose do the studies use?

A: The abstracts of the published mouse studies do not state a milligram figure, so there is nothing honest to quote. Where a route is stated it is intraperitoneal injection, and the authors note the compound lacks oral bioavailability (PMID 41421047). An animal study condition is not a recommendation and does not convert into a human dose.

Q: Would SLU-PP-332 show up on a drug test?

A: Assume yes if you are tested. WADA prohibits exercise mimetics and metabolic modulators in sport, and in 2026 two separate laboratories published in vitro metabolite maps for SLU-PP-332 explicitly to enable doping control detection (PMID 41688415, PMID 41588687).

Q: Is it the same thing as SLU-PP-915?

A: No. SLU-PP-915 is a chemically distinct pan-ERR agonist from the same research programme, built because SLU-PP-332 is not orally bioavailable (PMID 41421047). Both are preclinical. For compounds in the same metabolic territory with a longer published record, see MOTS-c and 5-Amino-1MQ.

Where to Get SLU-PP-332 in Vietnam

See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.

View Supply Index

Related Peptides

MOTS-c 5-Amino-1MQ NAD+ACE-031

Research & Sources

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity · Billon C, Sitaula S, Banerjee S, et al. · ACS Chemical Biology (2023) (PMID: 36988910)
The original report of SLU-PP-332. Mouse and cell line work only. The abstract states no milligram dose and no route.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome · Billon C, Schoepke E, Avdagic A, et al. · The Journal of Pharmacology and Experimental Therapeutics (2024) (PMID: 37739806)
Diet-induced obese and ob/ob mice. Reports increased energy expenditure, fatty acid oxidation and improved insulin sensitivity. The abstract states no dose.
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function · Xu W, Billon C, Li H, et al. · Circulation (2024) (PMID: 37961903)
Mouse pressure overload heart failure model. Identifies ERR gamma as the main mediator of the response. No human data.
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney · Wang XX, Myakala K, Libby AE, et al. · The American Journal of Pathology (2023) (PMID: 37717940)
Twenty-one-month-old mice treated for 8 weeks. The abstract states the duration but not the dose or route.
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity · Billon C, Appourchaux K, Côté I, Burris TP · The Journal of Pharmacology and Experimental Therapeutics (2026) (PMID: 41421047)
States that SLU-PP-332 was administered intraperitoneally and lacks oral bioavailability. This is the only abstract in this list that gives a route for SLU-PP-332.
Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study · Bonanni R, Falvino A, Matticari A, et al. · Frontiers in Physiology (2025) (PMID: 40692696)
Human myoblasts cultured from hip arthroplasty biopsies were treated with SLU-PP-332 in a dish. No person received the compound.
Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications · de Souza-Lima J, Astrosa-Martin BD, Galaz-Rodríguez CA, et al. · Revista Médica de Chile (2026) (PMID: 42024694)
Systematic review of the 2020 to 2024 animal and cell literature. Reports no evident toxicity in the obesity models covered and concludes clinical trials are needed in humans.
Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes · Avliyakulov NK, Sobolevsky T, Ahrens E · Drug Testing and Analysis (2026) (PMID: 41688415)
States that WADA prohibits exercise mimetics and metabolic modulators, and maps 22 in vitro metabolites for detection purposes.
In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential · Möller T, Krug O, Thevis M · Rapid Communications in Mass Spectrometry (2026) (PMID: 41588687)
Second independent metabolite characterisation, nine metabolites identified for SLU-PP-332, prepared for sports drug testing programmes.
Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling · Okda HE, Zhao P, Hayes M, et al. · International Journal of Biological Macromolecules (2026) (PMID: 41850449)
Structure activity relationship study describing SLU-PP-332 as a chemical probe and benchmark rather than a finished drug candidate.

Important Disclaimer

Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.